Novo Nordisk experimental obesity pill has mild-to-moderate side effects in early trial
Novo Nordisk's experimental weight-loss pill amycretin showed safe and tolerable results in an early-stage trial, with participants losing up to 13.1% of their weight after 12 weeks, primarily experiencing mild-to-moderate gastrointestinal side effects.
Reference News
Novo Nordisk's experimental weight-loss pill amycretin showed safe and tolerable results in an early-stage trial, with participants losing up to 13.1% of their weight after 12 weeks, primarily experiencing mild-to-moderate gastrointestinal side effects.
Novo Nordisk's experimental weight-loss pill amycretin showed safe and tolerable results in an early-stage trial, with participants losing up to 13.1% of their weight after 12 weeks, primarily experiencing mild-to-moderate gastrointestinal side effects.